BVAXF — BioVaxys Technology Corp.
—
OTC ·
Unknown ·
Unknown ·
CIK 1882559 ·
Last close
$0.15
Market Cap
$5.90M
52W High
$0.19
52W Low
$0.02
ADV30
50,439
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2025 | 0 | — | -1,290,159 | -1,316,689 | 1,100,321 | 4,309 | 3,831,367 |
| Jan 2025 | 0 | — | -1,205,557 | -1,070,198 | 1,281,310 | 157,415 | 3,024,088 |
| Oct 2024 | 0 | — | -1,499,245 | -2,743,983 | 1,300,764 | 211,806 | 3,220,886 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,916,300
Investing CF
$0
Financing CF
$2,483,685
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-33,637,271
Inventory
—
Receivables
$470,276
ST Investments
—
EBIT TTM
$-3,994,961
Pretax Income TTM
$-5,130,870
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Oct 2024 | 0 | -3,295,516 | -3,954,781 | 1,300,764 | 3,220,886 | — | -1,862,237 |
| Oct 2023 | 0 | -6,453,188 | -7,687,317 | 113,478 | 3,485,539 | — | -1,054,849 |
| Oct 2022 | 0 | -4,081,793 | -11,727,444 | 865,564 | 1,639,096 | — | -1,574,609 |
| Oct 2021 | 0 | -6,442,033 | -6,457,939 | 8,503,584 | 326,863 | — | -5,294,426 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NBLXF | Noble Plains Uranium Corp. | $5.92M | $0.08 | — |
| MWG | Multi Ways Holdings Ltd | $5.88M | $1.42 | — |
| XPON | Expion360 Inc. | $5.76M | $0.50 | — |
| VERTF | Vertiqal Studios Corp. | $5.75M | $0.01 | — |
| MITQ | MOVING iMAGE TECHNOLOGIES INC. | $5.71M | $0.57 | — |
News headlines (Yahoo Finance, 1h cache)
BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
2026-03-10 12:00 · Yahoo
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
2026-01-29 16:55 · Yahoo
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Ca
2026-01-20 13:00 · Yahoo
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
2026-01-08 13:00 · Yahoo
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
2025-12-17 13:00 · Yahoo
BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
2025-11-19 20:41 · Yahoo
BioVaxys Announces Extension of Life Offering Closing Date
2025-11-11 20:23 · Yahoo
BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
2025-10-30 20:54 · Yahoo
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
2025-10-28 11:00 · Yahoo
BioVaxys Technology Announces Conversion of Debentures
2025-10-22 11:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.